Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Ibrahim, Wanis H; Hammoudah, Mohammed; Akhtar, Naveed; Al-Hail, Hassan; Deleu, Dirk (2007)
Publisher: Co-Action Publishing
Journal: Libyan Journal of Medicine
Languages: English
Types: Article
There are few case reports documenting a new onset of demyelinating processes in patients receiving anti-tumour necrosis factor alpha therapy (anti-TNF alpha) for chronic inflammatory arthropathies. Whether anti-TNF alpha therapy induces new onset demyelination or just exacerbates pre-existing latent multiple sclerosis is not fully understood. We are reporting a 51-year-old woman without a prior history of multiple sclerosis, who developed demyelinating brain lesions three months after starting Etanercept. Her symptoms partially resolved on cessation of the drug. Our case was unusual compared to some previous case reports, as the patient’s age at presentation was beyond that for idiopathic multiple sclerosis. This may strengthen the hypothesis of a causal relationship between new onset demyelination and Etanercept; however, exacerbation of pre-existing demyelinating process by Etanercept in this patient still cannot be totally excluded. We recommend doing magnetic resonance imaging (MRI) of the brain before starting patients on anti-TNF alpha therapy to exclude latent demyelination. In addition, new onset demyelination following anti-TNF alpha therapy should be reported and studied thoroughly as this may yield a significant advancement in our understanding of the pathogenesis of multiple sclerosis. Long-term follow-up of these cases is also important to determine the long-term prognosis and the rate of relapse of demyelinating process in this group of patients.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Goronzy JJ and Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004; 16:212-17.
    • 2. Aringer M. T lymphocyte activation- an inside overview. Acta Med Austriaca. 2002; 29:7-12.
    • 3. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol suppl. 2002; 65:3-9.
    • 4. Suryaprasad AG and Prindiville T. The biology of TNF blockade. Autoimmun Rev. 2003; 2:346-57.
    • 5. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?. Rheumatology. 2005; 44(suppl.2): ii3-ii7.
    • 6. Moreland LW. Drugs that block tumor necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics. 2004; 39-53.
    • 7. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best practice & Research Rheumatology. 2006; 20(4):757-790.
    • 8. Enbrel® (etanercept). Prescribing information. Amgen Inc. 2004.
    • 9. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec; 44(12):2862-9.
    • 10. Owens T and Sriram S. The immunology of multiple sclerosis and its animal model Experimental allergic encephalomyelitis. Neurol Clin. 1995; 13:51-73.
    • 11. Kuroda Y and Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol. 1991; 34:159-64.
    • 12. Baker D, Butler D, Scallon BJ, et al. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor immunoglobulin fusion proteins. Eur J Immunol. 1994; 24:2040-8.
    • 13. Selmaj K, Raine CS, Cannella B, et al. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949-954.
    • 14. The Lenercept Multiple Sclerosis Study Group. TNF neutralization in multiple sclerosis: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology. 1999; 53:457-465.
    • 15. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody Ca2. Neurology. 1996; 47:1531-1534.
    • 16. Sukal SA, Nadiminti L and Granstein R. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dematol. 2006; 54(1):160-164.
    • 17. Mejico LS. Infliximab associated with retrobulbar optic neuritis. Arch Ophthalmol. 2004; 122: 793-794.
    • 18. Freeman HJ and Flak B. Demyelination - like syndrome in Crohn's disease after infliximab therapy. Canadian J Gastroenterology. 2005; 19:313-316.
    • 19. Thomas Jr, CW, Weinshenker BG and Sandborn WJ. Demyelination during anti-TNF alpha therapy with infliximab for Crohn's disease. Inflammatory Bowel dis. 2004; 10:28- 31.
    • 20. Sicotte NL and Voskuhl R. Onset of multiple sclerosis associated with anti-tumor necrosis factor therapy. Neurology. 2001; 57:1885-1888.
    • 21. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long-term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006; 65:379-384.
    • 22. Horneff G, Schmeling H, Beidermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004; 63:1638-1644.
    • 23. Titelbaum DS, Degenhardt A and Kinkel RP. Anti-Tumor Necrosis Factor AlphaAssociated multiple sclerosis. Am J Neuroradiol. 2005; 26:1548-1550.
    • 24. AL Saieg N and Luzar M. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatology. June 2006.
    • 25. Ruiz-Jimeno T, Carvajal A, Mata C, et al. Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis. J Rheumatology. July 2006.
    • 26. Tanno M, Nakamura I, Kobayashi S, et al. New onset demyelination induced by Infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol. 2006; 25:929-933.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from